Scinai Immunotherapeutics LT
13F holders, Q1 2025 (March 31)4holders
0new positions
0sold out
$2.69avg. 13F price*
At the end of Q1 2025, 4 institutions reported holding Scinai Immunotherapeutics LT in their 13F filings, unchanged from Q4 2024. 0 opened new positions and 0 sold out. The largest holders were UBS Group AG ($40K), Rhumbline Advisers ($4K) and Morgan Stanley ($687).
- Company
- Scinai Immunotherapeutics LT
- CUSIP
- 09073Q303
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 8,642 shares sold, net −8,642 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| UBS Group AG | 0.00% | Reduce -36.4% | 14,932 | $40K |
| Rhumbline Advisers | 0.00% | Reduce -5.2% | 1,567 | $4K |
| Morgan Stanley | 0.00% | No change | 255 | $687 |
| Credit Agricole S A | 0.00% | No change | 42 | $113 |
"% of holder's portfolio" is SCINAI IMMUNOTHERAPEUTICS LT's weight in each manager's 13F, not the share of Scinai Immunotherapeutics LT the manager owns.